Orion Corp has decided to concentrate future research on the development of new treatments for cancer and pain and discontinue work in neurodegeneration and rare diseases. The decision, announced on 24 March, comes as the Finnish company and its partner Bayer AG make regulatory applications in the US and EU for a new indication for Orion’s prostate cancer drug Nubeqa (darolutamide).
